Previous Close | 5.48 |
Open | 5.42 |
Bid | 0.00 x 0 |
Ask | 5.89 x 1100 |
Day's Range | 5.42 - 5.89 |
52 Week Range | 4.22 - 8.90 |
Volume | |
Avg. Volume | 7,158 |
Market Cap | 67.467M |
Beta (5Y Monthly) | 0.41 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.62 |
Earnings Date | May 22, 2024 - May 27, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.00 |
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen, today announced that it will report financial results for the full year of 2023 on Thursday, April 4, 2024, before the market open. The Company will then host a conference call and webcast to discuss its financial results and corporate updates on April 4th at 10:00 am Eastern Daylight Time.